Durability of neutralizing antibodies against yellow fever virus after vaccination in healthy adults.


Journal

Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899

Informations de publication

Date de publication:
24 04 2023
Historique:
received: 07 06 2022
revised: 07 12 2022
accepted: 10 03 2023
medline: 19 4 2023
pubmed: 27 3 2023
entrez: 26 3 2023
Statut: ppublish

Résumé

In accordance with the World Health Organization, one dose of yellow fever vaccine may guarantee protection lifelong in healthy adults. However, relatively little information is still available from ad hoc studies. We evaluated the persistence of neutralizing antibodies, which are considered to be an immune correlate of protection, in a large number of military personnel vaccinated up to 47 years before. Overall, 322 individuals were studied. The median time from vaccination to blood collection for neutralizing antibody evaluation was 9 years, ranging from <1 to 47 years. Of the 322 participants, 319 had neutralizing antibodies (99.1 %). The highest median PRNT

Identifiants

pubmed: 36967285
pii: S0264-410X(23)00284-0
doi: 10.1016/j.vaccine.2023.03.022
pii:
doi:

Substances chimiques

Antibodies, Neutralizing 0
Antibodies, Viral 0
Yellow Fever Vaccine 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2761-2763

Informations de copyright

Copyright © 2023 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Riccardo De Santis (R)

Scientific Department, Army Medical Center, Rome, Italy.

Giovanni Faggioni (G)

Scientific Department, Army Medical Center, Rome, Italy. Electronic address: giovanni.faggioni@gmail.com.

Alessandra Amoroso (A)

Scientific Department, Army Medical Center, Rome, Italy.

Andrea Ciammaruconi (A)

Scientific Department, Army Medical Center, Rome, Italy.

Alice Pomponi (A)

Scientific Department, Army Medical Center, Rome, Italy.

Maria Stella Lia (M)

Scientific Department, Army Medical Center, Rome, Italy.

Donatella Amatore (D)

Scientific Department, Army Medical Center, Rome, Italy.

Filippo Molinari (F)

Scientific Department, Army Medical Center, Rome, Italy.

Giancarlo Petralito (G)

Scientific Department, Army Medical Center, Rome, Italy.

Paola Stefanelli (P)

Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.

Giovanni Rezza (G)

Health Prevention Directorate, Ministry of Health, Rome, Italy.

Florigio Lista (F)

Scientific Department, Army Medical Center, Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH